Skip to main content
Premium Trial:

Request an Annual Quote

AGT Biosciences and ChemGenex Merge

NEW YORK, April 28 (GenomeWeb News) - AGT Biosciences of Melbourne, Australia, and ChemGenex Therapeutics of Menlo Park, Calif., yesterday announced a merger agreement.


AGT Biosciences, which lists Merck-Sante as a major shareholder, will issue 28 million shares of common stock to acquire all of the issued shares of privately held ChemGenex. Further financial details were not disclosed.


The combined entity will do business as ChemGenex Pharmaceuticals with Dennis Brown, CEO of ChemGenex,  serving as president of the combined firm. Brown co-founded Matrix Pharmaceutical, which was acquired by Chiron in 2002.


ChemGenex will maintain its Center for Statistical Genomics in San Antonio, Texas, the company said.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.